data_1qp2_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1qp2 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.1 ttm . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.053 0.454 . . . . 4.8399999999999999 110.115 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 58.7 t -90.04 100.05 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.539 -0.726 . . . . 2.5 110.088 -175.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -103.02 -176.14 3.0 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.537 -0.727 . . . . 2.6800000000000002 110.199 177.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -74.9 108.13 7.43 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.504 -0.747 . . . . 4.75 110.159 177.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 125.58 -29.92 4.6 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.597 -1.401 . . . . 0.92000000000000004 109.597 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.83 130.84 43.38 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.503 -0.998 . . . . 1.3500000000000001 110.21 179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 18.3 mtmt -91.26 138.12 31.83 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.558 -0.714 . . . . 2.4100000000000001 110.152 178.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 34.9 m -131.07 155.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.621 -0.674 . . . . 1.0700000000000001 110.308 -179.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -78.61 156.96 28.84 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 2.77 110.189 176.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.5 mm -99.29 121.61 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.593 -0.692 . . . . 1.0900000000000001 110.012 178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.403 ' N ' ' CD2' ' A' ' 11' ' ' LEU . 4.5 mm? -109.67 36.43 2.97 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.548 -0.72 . . . . 1.1299999999999999 110.102 177.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -109.99 97.89 31.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 2.5600000000000001 110.13 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HA ' ' CD2' ' A' ' 18' ' ' PHE . 50.1 Cg_exo -52.18 -25.49 23.5 Favored 'Trans proline' 0 N--CA 1.492 1.386 0 O-C-N 123.374 1.197 . . . . 0.41999999999999998 111.173 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -76.78 -26.63 54.7 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.537 -0.727 . . . . 2.27 110.361 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -75.49 129.91 38.03 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.555 -0.716 . . . . 1.6000000000000001 110.305 -176.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -58.16 -21.69 48.24 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.737 . . . . 2.3199999999999998 110.677 174.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.491 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.45 37.04 1.2 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.394 -0.816 . . . . 0.68999999999999995 110.413 -177.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.412 ' CE1' ' HG3' ' A' ' 19' ' ' GLN . 25.5 t80 -61.25 151.09 32.68 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.441 -0.787 . . . . 2.2400000000000002 110.172 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.412 ' HG3' ' CE1' ' A' ' 18' ' ' PHE . 24.9 mt-30 52.73 43.3 31.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.438 -0.789 . . . . 1.9399999999999999 110.779 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.92 145.12 34.19 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.512 -0.742 . . . . 1.3799999999999999 110.167 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 60.8 t -92.55 123.14 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.556 -0.715 . . . . 1.0900000000000001 109.938 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -111.25 -170.73 19.12 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.508 -1.437 . . . . 0.27000000000000002 109.508 177.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 13.8 m -123.32 143.1 50.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.576 -0.955 . . . . 1.1100000000000001 110.235 178.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -78.84 119.59 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.588 -0.695 . . . . 1.1399999999999999 109.964 178.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.82 -45.45 11.57 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.678 -0.639 . . . . 1.1000000000000001 110.18 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -161.61 162.33 30.0 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.548 -0.72 . . . . 1.6499999999999999 110.205 179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t -121.43 120.03 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.555 -0.716 . . . . 1.29 109.784 178.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -97.43 127.62 43.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.575 -0.703 . . . . 1.5700000000000001 110.211 178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 8.1 tt0 -115.01 82.0 1.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.556 -0.715 . . . . 4.1600000000000001 110.213 178.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.6 m -144.42 -45.24 0.25 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.521 -0.737 . . . . 2.3500000000000001 110.22 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.09 83.21 0.04 OUTLIER Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.545 -1.422 . . . . 2.1299999999999999 109.545 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -136.65 163.21 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.559 -0.965 . . . . 1.6799999999999999 110.281 178.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.412 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.0 ptpt -59.81 -26.4 65.74 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.577 -0.702 . . . . 2.6400000000000001 110.419 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.412 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 37.0 m-85 -138.24 96.32 10.08 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.457 -0.777 . . . . 2.0699999999999998 110.183 177.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -52.85 -41.76 68.2 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.421 1.221 . . . . 0.52000000000000002 111.13 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.05 139.85 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.413 -0.804 . . . . 1.1100000000000001 110.025 -173.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 9.0 mt -100.78 135.27 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.551 -0.718 . . . . 1.47 109.892 177.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.413 HG11 ' CZ ' ' A' ' 40' ' ' PHE . 57.4 t -118.87 152.57 21.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.578 -0.702 . . . . 1.0800000000000001 110.013 178.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 6.4 ttm180 -119.05 151.27 38.55 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.574 -0.704 . . . . 3.1499999999999999 110.206 178.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.491 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 44.0 m-85 -130.55 172.95 11.35 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.545 -0.722 . . . . 2.2400000000000002 110.238 179.293 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -110.18 -29.53 8.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.544 -0.722 . . . . 1.9299999999999999 110.175 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.3 ttmt -89.39 171.55 9.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.581 -0.699 . . . . 3.2799999999999998 110.214 179.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -112.68 -172.61 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.585 -0.697 . . . . 1.3200000000000001 110.236 176.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 43.5 p-10 -134.88 -165.43 1.67 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.56 -0.713 . . . . 1.29 110.31 178.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.62 -28.56 69.71 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.57 -0.706 . . . . 2.1699999999999999 110.229 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -81.98 -28.89 32.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.499 -0.751 . . . . 1.3999999999999999 110.22 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 91.13 53.06 2.26 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.532 -1.427 . . . . 0.94999999999999996 109.532 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 77.0 mt -112.43 164.24 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.573 -0.957 . . . . 1.3300000000000001 109.982 179.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 13.9 p-10 -123.16 -39.39 2.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.595 -0.69 . . . . 1.77 110.349 179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.6 p -120.29 154.32 35.14 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.579 -0.701 . . . . 1.23 110.191 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -151.51 -170.2 3.59 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.569 -0.707 . . . . 1.9299999999999999 110.182 178.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -129.4 132.62 47.06 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.571 -0.706 . . . . 0.78000000000000003 110.24 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.433 ' N ' ' CD1' ' A' ' 60' ' ' PHE . 61.0 m-85 -129.85 159.22 37.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.569 -0.707 . . . . 2.1800000000000002 110.249 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -87.29 149.12 24.76 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.706 . . . . 1.0800000000000001 110.21 177.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -59.99 -37.27 79.16 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.563 -0.711 . . . . 1.7 110.453 -175.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -62.32 -25.75 68.05 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.578 -0.702 . . . . 1.0900000000000001 110.428 -179.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -96.59 27.81 3.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.514 -0.741 . . . . 0.88 110.372 179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 88.8 mt -138.65 140.65 38.95 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.548 -0.72 . . . . 1.04 110.224 177.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -112.54 141.46 28.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.546 -0.721 . . . . 1.0700000000000001 109.921 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -77.81 116.97 18.74 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.677 . . . . 2.3500000000000001 110.134 178.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.8 m -137.01 62.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.611 -0.681 . . . . 1.0800000000000001 110.264 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -83.9 162.48 20.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.552 -0.718 . . . . 2.5899999999999999 110.254 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.19 111.62 4.24 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.574 -0.703 . . . . 3.8700000000000001 110.179 178.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.13 161.05 3.82 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 O-C-N 123.124 1.065 . . . . 5.4900000000000002 110.972 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -82.3 140.82 33.37 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.591 -0.693 . . . . 7.6200000000000001 110.229 178.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -90.03 50.16 1.83 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.626 -0.671 . . . . 7.6399999999999997 110.272 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -168.02 81.44 0.81 Allowed Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.555 -0.716 . . . . 11.32 110.171 177.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.05 -63.0 0.27 Allowed 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.353 1.186 . . . . 10.550000000000001 110.989 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.9 tptp -167.26 122.6 1.07 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 14.1 110.229 178.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 30.7 mttt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 118.032 -0.985 . . . . 14.52 110.234 179.515 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.1 ttm . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.053 0.454 . . . . 4.52 110.115 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.488 ' CG1' HG21 ' A' ' 24' ' ' VAL . 58.7 t -90.04 100.05 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.539 -0.726 . . . . 1.89 110.088 -175.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -103.02 -176.14 3.0 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.537 -0.727 . . . . 2.68 110.199 177.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -74.9 108.13 7.43 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.504 -0.747 . . . . 4.15 110.159 177.155 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 125.58 -29.92 4.6 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.597 -1.401 . . . . 0.7 109.597 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . 0.405 ' O ' HG23 ' A' ' 24' ' ' VAL . 0.3 OUTLIER -69.83 130.84 43.38 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.503 -0.998 . . . . 1.14 110.21 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.416 ' HB3' HG12 ' A' ' 21' ' ' VAL . 18.3 mtmt -91.26 138.12 31.83 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.558 -0.714 . . . . 1.96 110.152 178.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.412 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -131.07 155.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.621 -0.674 . . . . 0.2 110.308 -179.21 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.765 ' HG2' HG21 ' A' ' 68' ' ' VAL . 3.1 mmt180 -78.61 156.96 28.84 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 2.04 110.189 176.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.602 HD11 HG11 ' A' ' 38' ' ' VAL . 49.5 mm -99.29 121.61 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.593 -0.692 . . . . 0.24 110.012 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.562 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -109.67 36.43 2.97 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.548 -0.72 . . . . 0.39 110.102 177.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -109.99 97.89 31.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 1.89 110.13 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.18 -25.49 23.5 Favored 'Trans proline' 0 N--CA 1.492 1.386 0 O-C-N 123.374 1.197 . . . . 0.39 111.173 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -76.78 -26.63 54.7 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.537 -0.727 . . . . 2.27 110.361 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -75.49 129.91 38.03 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.555 -0.716 . . . . 1.22 110.305 -176.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -58.16 -21.69 48.24 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.737 . . . . 1.42 110.677 174.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.491 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.45 37.04 1.2 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.394 -0.816 . . . . 0.57 110.413 -177.293 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CE1' ' HG3' ' A' ' 19' ' ' GLN . 25.5 t80 -61.25 151.09 32.68 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.441 -0.787 . . . . 1.31 110.172 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.409 ' HG3' ' CE1' ' A' ' 18' ' ' PHE . 24.9 mt-30 52.73 43.3 31.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.438 -0.789 . . . . 1.58 110.779 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.92 145.12 34.19 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.512 -0.742 . . . . 1.38 110.167 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.442 HG22 ' HG2' ' A' ' 9' ' ' ARG . 60.8 t -92.55 123.14 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.556 -0.715 . . . . 0.36 109.938 -179.023 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -111.25 -170.73 19.12 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.508 -1.437 . . . . 0.27 109.508 177.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 13.8 m -123.32 143.1 50.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.576 -0.955 . . . . 0.29 110.235 178.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.488 HG21 ' CG1' ' A' ' 2' ' ' VAL . 57.3 t -78.84 119.59 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.588 -0.695 . . . . 0.39 109.964 178.021 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.82 -45.45 11.57 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.678 -0.639 . . . . 0.39 110.18 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.662 ' O ' HD12 ' A' ' 37' ' ' ILE . 0.6 OUTLIER -161.61 162.33 30.0 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.548 -0.72 . . . . 1.29 110.205 179.397 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t -121.43 120.03 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.555 -0.716 . . . . 0.71 109.784 178.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -97.43 127.62 43.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.575 -0.703 . . . . 1.57 110.211 178.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 8.1 tt0 -115.01 82.0 1.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.556 -0.715 . . . . 3.64 110.213 178.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.6 m -144.42 -45.24 0.25 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.521 -0.737 . . . . 2.35 110.22 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.09 83.21 0.04 OUTLIER Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.545 -1.422 . . . . 1.78 109.545 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.401 HD11 ' HA ' ' A' ' 35' ' ' PRO . 44.8 pt -136.65 163.21 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.559 -0.965 . . . . 1.1 110.281 178.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.404 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.0 ptpt -59.81 -26.4 65.74 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.577 -0.702 . . . . 2.12 110.419 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.404 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 37.0 m-85 -138.24 96.32 10.08 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.457 -0.777 . . . . 1.23 110.183 177.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.401 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.0 Cg_exo -52.85 -41.76 68.2 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.421 1.221 . . . . 0.52 111.13 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.05 139.85 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.413 -0.804 . . . . 0.42 110.025 -173.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.662 HD12 ' O ' ' A' ' 26' ' ' SER . 9.0 mt -100.78 135.27 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.551 -0.718 . . . . 0.83 109.892 177.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.602 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -118.87 152.57 21.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.578 -0.702 . . . . 0.33 110.013 178.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.435 ' HG3' HG22 ' A' ' 57' ' ' THR . 6.4 ttm180 -119.05 151.27 38.55 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.574 -0.704 . . . . 2.62 110.206 178.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.491 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 44.0 m-85 -130.55 172.95 11.35 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.545 -0.722 . . . . 1.32 110.238 179.293 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -110.18 -29.53 8.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.544 -0.722 . . . . 1.93 110.175 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.3 ttmt -89.39 171.55 9.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.581 -0.699 . . . . 2.82 110.214 179.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -112.68 -172.61 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.585 -0.697 . . . . 0.79 110.236 176.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.606 HD21 HD12 ' A' ' 55' ' ' ILE . 43.5 p-10 -134.88 -165.43 1.67 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.56 -0.713 . . . . 1.23 110.31 178.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.62 -28.56 69.71 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.57 -0.706 . . . . 1.39 110.229 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -81.98 -28.89 32.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.499 -0.751 . . . . 1.4 110.22 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 91.13 53.06 2.26 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.532 -1.427 . . . . 0.86 109.532 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.606 HD12 HD21 ' A' ' 44' ' ' ASN . 77.0 mt -112.43 164.24 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.573 -0.957 . . . . 0.76 109.982 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.42 ' N ' HG22 ' A' ' 55' ' ' ILE . 13.9 p-10 -123.16 -39.39 2.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.595 -0.69 . . . . 1.28 110.349 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.435 HG22 ' HG3' ' A' ' 39' ' ' ARG . 7.6 p -120.29 154.32 35.14 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.579 -0.701 . . . . 0.61 110.191 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -151.51 -170.2 3.59 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.569 -0.707 . . . . 1.22 110.182 178.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -129.4 132.62 47.06 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.571 -0.706 . . . . 0.58 110.24 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 61.0 m-85 -129.85 159.22 37.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.569 -0.707 . . . . 1.27 110.249 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.461 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -87.29 149.12 24.76 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.706 . . . . 0.26 110.21 177.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -59.99 -37.27 79.16 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.563 -0.711 . . . . 1.7 110.453 -175.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.461 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 11.7 p-10 -62.32 -25.75 68.05 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.578 -0.702 . . . . 1.09 110.428 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.433 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 59.4 mt-10 -96.59 27.81 3.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.514 -0.741 . . . . 0.88 110.372 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.412 HD22 HG23 ' A' ' 8' ' ' VAL . 88.8 mt -138.65 140.65 38.95 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.548 -0.72 . . . . 0.33 110.224 177.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -112.54 141.46 28.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.546 -0.721 . . . . 0.29 109.921 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -77.81 116.97 18.74 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.677 . . . . 2.35 110.134 178.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.765 HG21 ' HG2' ' A' ' 9' ' ' ARG . 35.8 m -137.01 62.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.611 -0.681 . . . . 0.84 110.264 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -83.9 162.48 20.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.552 -0.718 . . . . 2.59 110.254 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.19 111.62 4.24 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.574 -0.703 . . . . 3.42 110.179 178.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.13 161.05 3.82 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 O-C-N 123.124 1.065 . . . . 4.81 110.972 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -82.3 140.82 33.37 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.591 -0.693 . . . . 7.19 110.229 178.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -90.03 50.16 1.83 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.626 -0.671 . . . . 7.16 110.272 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -168.02 81.44 0.81 Allowed Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.555 -0.716 . . . . 10.98 110.171 177.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.05 -63.0 0.27 Allowed 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.353 1.186 . . . . 10.08 110.989 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.9 tptp -167.26 122.6 1.07 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 13.8 110.229 178.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 30.7 mttt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 118.032 -0.985 . . . . 14.16 110.234 179.515 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.1 ttm . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.053 0.454 . . . . 4.52 110.115 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.488 ' CG1' HG21 ' A' ' 24' ' ' VAL . 58.7 t -90.04 100.05 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.539 -0.726 . . . . 1.89 110.088 -175.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -103.02 -176.14 3.0 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.537 -0.727 . . . . 2.68 110.199 177.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -74.9 108.13 7.43 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.504 -0.747 . . . . 4.15 110.159 177.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 125.58 -29.92 4.6 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.597 -1.401 . . . . 0.7 109.597 -179.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . 0.405 ' O ' HG23 ' A' ' 24' ' ' VAL . 0.3 OUTLIER -69.83 130.84 43.38 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.503 -0.998 . . . . 1.14 110.21 179.168 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.416 ' HB3' HG12 ' A' ' 21' ' ' VAL . 18.3 mtmt -91.26 138.12 31.83 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.558 -0.714 . . . . 1.96 110.152 178.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.412 HG23 HD22 ' A' ' 65' ' ' LEU . 34.9 m -131.07 155.78 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.621 -0.674 . . . . 0.2 110.308 -179.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.765 ' HG2' HG21 ' A' ' 68' ' ' VAL . 3.1 mmt180 -78.61 156.96 28.84 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.604 -0.685 . . . . 2.04 110.189 176.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.602 HD11 HG11 ' A' ' 38' ' ' VAL . 49.5 mm -99.29 121.61 50.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.593 -0.692 . . . . 0.24 110.012 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.562 HD22 ' C ' ' A' ' 10' ' ' ILE . 4.5 mm? -109.67 36.43 2.97 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.548 -0.72 . . . . 0.39 110.102 177.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -109.99 97.89 31.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 1.89 110.13 -179.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -52.18 -25.49 23.5 Favored 'Trans proline' 0 N--CA 1.492 1.386 0 O-C-N 123.374 1.197 . . . . 0.39 111.173 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -76.78 -26.63 54.7 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.537 -0.727 . . . . 2.27 110.361 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -75.49 129.91 38.03 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.555 -0.716 . . . . 1.22 110.305 -176.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.1 t80 -58.16 -21.69 48.24 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.521 -0.737 . . . . 1.42 110.677 174.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.491 ' CE3' ' CD2' ' A' ' 40' ' ' PHE . 5.4 m-90 -95.45 37.04 1.2 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.394 -0.816 . . . . 0.57 110.413 -177.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.409 ' CE1' ' HG3' ' A' ' 19' ' ' GLN . 25.5 t80 -61.25 151.09 32.68 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.441 -0.787 . . . . 1.31 110.172 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.409 ' HG3' ' CE1' ' A' ' 18' ' ' PHE . 24.9 mt-30 52.73 43.3 31.53 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.438 -0.789 . . . . 1.58 110.779 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.92 145.12 34.19 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.512 -0.742 . . . . 1.38 110.167 176.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.442 HG22 ' HG2' ' A' ' 9' ' ' ARG . 60.8 t -92.55 123.14 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.556 -0.715 . . . . 0.36 109.938 -179.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -111.25 -170.73 19.12 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.508 -1.437 . . . . 0.27 109.508 177.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 13.8 m -123.32 143.1 50.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.576 -0.955 . . . . 0.29 110.235 178.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.488 HG21 ' CG1' ' A' ' 2' ' ' VAL . 57.3 t -78.84 119.59 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.588 -0.695 . . . . 0.39 109.964 178.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -85.82 -45.45 11.57 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.678 -0.639 . . . . 0.39 110.18 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.662 ' O ' HD12 ' A' ' 37' ' ' ILE . 0.6 OUTLIER -161.61 162.33 30.0 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.548 -0.72 . . . . 1.29 110.205 179.397 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.5 t -121.43 120.03 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.555 -0.716 . . . . 0.71 109.784 178.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -97.43 127.62 43.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.575 -0.703 . . . . 1.57 110.211 178.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLN . . . . . . . . . . . . . 8.1 tt0 -115.01 82.0 1.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.556 -0.715 . . . . 3.64 110.213 178.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 6.6 m -144.42 -45.24 0.25 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.521 -0.737 . . . . 2.35 110.22 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.09 83.21 0.04 OUTLIER Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.545 -1.422 . . . . 1.78 109.545 178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.401 HD11 ' HA ' ' A' ' 35' ' ' PRO . 44.8 pt -136.65 163.21 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.559 -0.965 . . . . 1.1 110.281 178.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.404 ' HG3' ' CD2' ' A' ' 34' ' ' TYR . 5.0 ptpt -59.81 -26.4 65.74 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.577 -0.702 . . . . 2.12 110.419 -178.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.404 ' CD2' ' HG3' ' A' ' 33' ' ' LYS . 37.0 m-85 -138.24 96.32 10.08 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.457 -0.777 . . . . 1.23 110.183 177.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.401 ' HA ' HD11 ' A' ' 32' ' ' ILE . 50.0 Cg_exo -52.85 -41.76 68.2 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.421 1.221 . . . . 0.52 111.13 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.05 139.85 17.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.413 -0.804 . . . . 0.42 110.025 -173.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.662 HD12 ' O ' ' A' ' 26' ' ' SER . 9.0 mt -100.78 135.27 37.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.551 -0.718 . . . . 0.83 109.892 177.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.602 HG11 HD11 ' A' ' 10' ' ' ILE . 57.4 t -118.87 152.57 21.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.578 -0.702 . . . . 0.33 110.013 178.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.435 ' HG3' HG22 ' A' ' 57' ' ' THR . 6.4 ttm180 -119.05 151.27 38.55 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.574 -0.704 . . . . 2.62 110.206 178.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.491 ' CD2' ' CE3' ' A' ' 17' ' ' TRP . 44.0 m-85 -130.55 172.95 11.35 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.545 -0.722 . . . . 1.32 110.238 179.293 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -110.18 -29.53 8.14 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.544 -0.722 . . . . 1.93 110.175 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 11.3 ttmt -89.39 171.55 9.67 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.581 -0.699 . . . . 2.82 110.214 179.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.6 m -112.68 -172.61 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.585 -0.697 . . . . 0.79 110.236 176.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.606 HD21 HD12 ' A' ' 55' ' ' ILE . 43.5 p-10 -134.88 -165.43 1.67 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.56 -0.713 . . . . 1.23 110.31 178.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -64.62 -28.56 69.71 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.57 -0.706 . . . . 1.39 110.229 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -81.98 -28.89 32.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.499 -0.751 . . . . 1.4 110.22 179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 91.13 53.06 2.26 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.532 -1.427 . . . . 0.86 109.532 179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.606 HD12 HD21 ' A' ' 44' ' ' ASN . 77.0 mt -112.43 164.24 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.573 -0.957 . . . . 0.76 109.982 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.42 ' N ' HG22 ' A' ' 55' ' ' ILE . 13.9 p-10 -123.16 -39.39 2.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.595 -0.69 . . . . 1.28 110.349 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.435 HG22 ' HG3' ' A' ' 39' ' ' ARG . 7.6 p -120.29 154.32 35.14 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.579 -0.701 . . . . 0.61 110.191 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -151.51 -170.2 3.59 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.569 -0.707 . . . . 1.22 110.182 178.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -129.4 132.62 47.06 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.571 -0.706 . . . . 0.58 110.24 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.433 ' CD1' ' N ' ' A' ' 60' ' ' PHE . 61.0 m-85 -129.85 159.22 37.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.569 -0.707 . . . . 1.27 110.249 178.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.461 ' HB1' ' OD1' ' A' ' 63' ' ' ASP . . . -87.29 149.12 24.76 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.706 . . . . 0.26 110.21 177.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -59.99 -37.27 79.16 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.563 -0.711 . . . . 1.7 110.453 -175.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.461 ' OD1' ' HB1' ' A' ' 61' ' ' ALA . 11.7 p-10 -62.32 -25.75 68.05 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.578 -0.702 . . . . 1.09 110.428 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.433 ' OE1' ' HB3' ' A' ' 61' ' ' ALA . 59.4 mt-10 -96.59 27.81 3.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.514 -0.741 . . . . 0.88 110.372 179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.412 HD22 HG23 ' A' ' 8' ' ' VAL . 88.8 mt -138.65 140.65 38.95 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.548 -0.72 . . . . 0.33 110.224 177.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.5 t -112.54 141.46 28.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.546 -0.721 . . . . 0.29 109.921 176.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -77.81 116.97 18.74 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.617 -0.677 . . . . 2.35 110.134 178.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.765 HG21 ' HG2' ' A' ' 9' ' ' ARG . 35.8 m -137.01 62.85 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.611 -0.681 . . . . 0.84 110.264 -179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -83.9 162.48 20.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.552 -0.718 . . . . 2.59 110.254 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.19 111.62 4.24 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.574 -0.703 . . . . 3.42 110.179 178.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.13 161.05 3.82 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 O-C-N 123.124 1.065 . . . . 4.81 110.972 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -82.3 140.82 33.37 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.591 -0.693 . . . . 7.19 110.229 178.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -90.03 50.16 1.83 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.626 -0.671 . . . . 7.16 110.272 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -168.02 81.44 0.81 Allowed Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.555 -0.716 . . . . 10.98 110.171 177.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.05 -63.0 0.27 Allowed 'Trans proline' 0 N--CA 1.492 1.4 0 O-C-N 123.353 1.186 . . . . 10.08 110.989 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 5.9 tptp -167.26 122.6 1.07 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.519 -0.738 . . . . 13.8 110.229 178.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 30.7 mttt . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 118.032 -0.985 . . . . 14.16 110.234 179.515 . . . . . . . . 0 0 . 1 stop_ save_